| Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. | None |
| Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells. | None |
| Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. | None |
| Oxidant-induced restriction polymorphism maps to kinase region of c-abl oncogene. | None |
| MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. | None |
| Clonally related IL-7-independent tumors induced by oncogenes abl + myc or raf + myc have reduced sensitivity to TGF-beta1. | None |
| BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. | None |
| The abl oncogene family and apoptosis. | None |
| Regulation of cellular transformation by oncogenic and normal Abl kinases. | None |
| Expression of the mouse c-abl type IV proto-oncogene product in the insect cell baculovirus system. | None |
| Ubp43 deficiency increases the resistance to oncogenic transformation by BCR-ABL | None |
| Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein. | None |
| High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. | None |
| ds-Oligonucleotide-peptide conjugates featuring peptides from the leucine-zipper region of Fos as switchable receptors for the oncoprotein Jun. | None |
| Differential repression of c-myc and cdc2 gene expression by ERF and PE-1/METS. | None |
| ERF is targeted for inactivation by transforming oncogenes such as vAbl. | None |
| Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. | None |
| An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras. | None |
| Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. | None |
| These results demonstrate that allele-specific changes in gene expression, with selective, progressive silencing of the wild-type ABL1 allele in favor of the oncogenic BCR-ABL1 allele occur in CML patients with therapy-resistant disease. | None |